{"summary":"I am the Head of the Oncology and Biosimilars team at Clarivate where I lead a global team of 30 experts in the production of syndicated primary and secondary market research solutions and custom analysis of a wide range of oncology indications. I assist clients by providing strategic insights into competitive landscapes and opportunities in oncology. I have more than a decade of experience in oncology market research, forecasting and a broad knowledge of oncology indications and their markets and the wider healthcare industry.","lastName":"Webster","objectUrn":"urn:li:member:32567855","geoRegion":"United Kingdom","fullName":"Rachel Webster","firstName":"Rachel","currentPositions":[{"companyName":"Clarivate","title":"Head of Oncology and Biosimilars","tenureAtCompany":{"numYears":2,"numMonths":11},"companyUrnResolutionResult":{"employeeCountRange":"10001+","headquarters":{"country":"United Kingdom","city":"London"},"website":"https:\/\/www.clarivate.com\/","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/clarivate\/","industry":"Information Services"},"startedOn":{"month":7,"year":2021},"companyUrn":"urn:li:fs_salesCompany:10950962"}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1655298320614?e=1723075200&v=beta&t=hcx4jLauCPxVH8PRuvFq08_z_4r31xu5QQbf0-KBkSk","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1655298320614?e=1723075200&v=beta&t=ysCeWQNLbz2O9kuu-IQoJb7WSR0GiHIdm5nl6QLcsDw","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1655298320614?e=1723075200&v=beta&t=cYxvw_sUhMZV9smPsRiZre-vHFhCueXNLIZxSgqDWU8","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1655298320614?e=1723075200&v=beta&t=J0Lur0yCWNiEUXiVX91vK0zy7G5XgVnNwmkoMVLE7YY","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C4E03AQEpuvVUTgGOSg\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{"socialHandles":[{"type":"TWITTER","name":"RWebsterDRG","dataSource":"LINKEDIN"}]},"industry":"Hospitals and Health Care","educations":[{"endedOn":{"month":8,"year":2006},"degree":"D.Phil","eduId":805683111,"schoolUrn":"urn:li:fs_salesSchool:4477","school":"urn:li:fs_salesSchool:4477","fieldsOfStudy":["Biochemistry and Molecular Biology"],"schoolName":"University of Oxford","startedOn":{"month":9,"year":2002}},{"endedOn":{"year":2006},"degree":"DPhil","eduId":25751648,"schoolUrn":"urn:li:fs_salesSchool:4477","school":"urn:li:fs_salesSchool:4477","fieldsOfStudy":["molecular biology\/biochemistry"],"startedOn":{"year":2002}},{"endedOn":{"year":2002},"degree":"MSc","eduId":29709544,"schoolUrn":"urn:li:fs_salesSchool:4477","school":"urn:li:fs_salesSchool:4477","fieldsOfStudy":["Environmental Management"],"startedOn":{"year":2001}},{"endedOn":{"year":2001},"degree":"BA (Hons)","eduId":29709648,"schoolUrn":"urn:li:fs_salesSchool:4477","school":"urn:li:fs_salesSchool:4477","fieldsOfStudy":["Biological Sciences"],"startedOn":{"year":1998}}],"skills":[{"numOfEndorsement":7,"name":"Lifesciences"},{"numOfEndorsement":15,"name":"Biotechnology"},{"numOfEndorsement":13,"name":"Competitive Intelligence"},{"numOfEndorsement":18,"name":"Pharmaceutical Industry"},{"numOfEndorsement":14,"name":"Oncology"},{"numOfEndorsement":1,"name":"Molecular Biology"},{"numOfEndorsement":2,"name":"Data Analysis"},{"numOfEndorsement":2,"name":"Immunology"},{"numOfEndorsement":2,"name":"Drug Discovery"},{"numOfEndorsement":8,"name":"Biopharmaceuticals"},{"numOfEndorsement":1,"name":"Clinical Development"},{"numOfEndorsement":0,"name":"Drug Development"},{"numOfEndorsement":10,"name":"Market Research"},{"numOfEndorsement":2,"name":"Medical Writing"},{"numOfEndorsement":9,"name":"Life Sciences"},{"numOfEndorsement":9,"name":"Market Analysis"}],"numOfConnections":718,"patents":[],"headline":"Director and Head of Oncology & Biosimilars at Clarivate","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/websterrachel","organizations":[],"location":"United Kingdom","publications":[{"publishedOn":{"month":7,"day":1,"year":2014},"description":"News and analysis of the market landscape for malignant melanoma \u2014 a cancer for which treatment options have broadened substantially in recent years, with several new drugs also soon expected to gain approval.","url":"http:\/\/www.nature.com\/nrd\/journal\/v13\/n7\/full\/nrd4326.html","name":"The Malignant Melanoma Landscape","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"}]},{"publishedOn":{"month":12,"day":1,"year":2014},"description":"Checkpoint inhibitors, which stimulate the anticancer activity of T cells, are the most advanced class of cancer immunotherapies. This analysis examines the pipeline of agents in development and their market potential.","url":"http:\/\/www.nature.com\/nrd\/journal\/v13\/n12\/full\/nrd4476.html","name":"The Immune Checkpoint Inhibitors: Where Are We Now?","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"}]},{"publishedOn":{"month":2,"day":1,"year":2016},"description":"This analysis presents anticancer drug combinations that contain two or more targeted agents and discusses their impact on oncology markets.","url":"http:\/\/www.nature.com\/nrd\/journal\/v15\/n2\/full\/nrd.2016.3.html","name":"Combination Therapies in Oncology","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"}]},{"publishedOn":{"month":4,"day":1,"year":2016},"description":"The year 2015 saw the approval of six new targeted therapies for the treatment of non-small-cell lung cancer (NSCLC). This analysis discusses recently approved as well as late-phase compounds and examines how different drug classes will affect the NSCLC market.","url":"http:\/\/www.nature.com\/nrd\/journal\/v15\/n4\/full\/nrd.2016.42.html","name":"The Non-Small-Cell Lung Cancer Market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHq3HYBmo5LNgFVoJBkL8regfojP87-EdE,NAME_SEARCH,dvus)"}]},{"publishedOn":{"month":1,"day":13,"year":2017},"description":"News and analysis of the market landscape for squamous cell carcinoma of the head and neck. ","url":"https:\/\/www.nature.com\/articles\/nrd.2016.261","name":"The SCCHN drug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"}]},{"publishedOn":{"month":5,"day":26,"year":2017},"description":"News and analysis of the ovarian cancer pipeline and market - PARP inhibitors and beyond","url":"https:\/\/www.nature.com\/articles\/nrd.2017.92","name":"The Ovarian Cancer Drug Market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"}]},{"publishedOn":{"month":3,"day":1,"year":2018},"description":"News and analysis of the chimeric antigen receptor T-cell therapy pipeline and market","url":"http:\/\/www.nature.com\/articles\/nrd.2017.266","name":"The market for chimeric antigen receptor T cell therapies","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"}]},{"publishedOn":{"month":4,"day":3,"year":2018},"description":"News and analysis of the gastroesophageal cancer pipeline and market - the impact of immune checkpoint inhibitor approvals","url":"http:\/\/www.nature.com\/articles\/nrd.2018.35","name":"The gastroesophageal cancer drug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"}]},{"publishedOn":{"month":8,"day":31,"year":2018},"description":"News and analysis of the hepatocellular carcinoma landscape - recent approvals of kinase inhibitors and immune checkpoint inhibitors, key therapies in the pipeline and impact on the market","url":"https:\/\/www.nature.com\/articles\/nrd.2018.146","name":"The hepatocellular carcinoma market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcbo04BbV0-869Aff7jsMH7JxKoziS_pP4,NAME_SEARCH,VvHx)"}]},{"publishedOn":{"month":2,"day":18,"year":2019},"description":"News and analysis of the multiple myeloma market","url":"https:\/\/www.nature.com\/articles\/d41573-019-00031-w","name":"The multiple myeloma drug market","publisher":"Narture Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAwg9OIBQxn6-cwr9Zx10bLHw5CR_YQtNyA,NAME_SEARCH,vpqC)"}]},{"publishedOn":{"month":8,"day":9,"year":2019},"description":"News and analysis of the acute myeloid leukaemia market","url":"https:\/\/www.nature.com\/articles\/d41573-019-00142-4","name":"The acute myeloid leukaemia market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6M38BFA6C8zulfVSEUHInyur796PWvlU,NAME_SEARCH,D-5_)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAQvGZsBQsQPqiYByIB78dFsElqpdmksvg8,NAME_SEARCH,rSeg)"}]},{"publishedOn":{"month":1,"day":28,"year":2020},"description":"News and analysis of the tumour-agnostic therapies landscape.","url":"https:\/\/www.nature.com\/articles\/d41573-020-00015-1","name":"Tumour-Agnostic Therapies","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHq3HYBmo5LNgFVoJBkL8regfojP87-EdE,NAME_SEARCH,dvus)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABeqrQYBUQUmOv_m_Lj7IDiCLCSlokO1MKw,NAME_SEARCH,AQpQ)"}]},{"publishedOn":{"month":3,"day":31,"year":2020},"description":"News and analysis of the small-cell lung cancer market","url":"https:\/\/www.nature.com\/articles\/d41573-020-00057-5","name":"The small-cell lung cancer drug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcbo04BbV0-869Aff7jsMH7JxKoziS_pP4,NAME_SEARCH,VvHx)"}]},{"publishedOn":{"month":1,"day":22,"year":2021},"description":"News and analysis of the breast cancer drug market","url":"https:\/\/www.nature.com\/articles\/d41573-021-00018-6","name":"The breast cancer drug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAwg9OIBQxn6-cwr9Zx10bLHw5CR_YQtNyA,NAME_SEARCH,vpqC)"}]},{"publishedOn":{"month":3,"day":24,"year":2021},"description":"News and analysis of the oncology market for antibody-drug conjugates","url":"https:\/\/www.nature.com\/articles\/d41573-021-00054-2","name":"The oncology market for antibody-drug conjugates","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAB8V1V8BiglikWKpUiOEBtbl_ENGHCBhVmQ,NAME_SEARCH,ajvl)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHq3HYBmo5LNgFVoJBkL8regfojP87-EdE,NAME_SEARCH,dvus)"}]},{"publishedOn":{"month":6,"day":16,"year":2021},"description":"News and analysis of the prostate cancer drug market","url":"https:\/\/www.nature.com\/articles\/d41573-021-00111-w","name":"The prostate cancer drug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAB8V1V8BiglikWKpUiOEBtbl_ENGHCBhVmQ,NAME_SEARCH,ajvl)"}]},{"publishedOn":{"month":1,"day":21,"year":2022},"description":"News and analysis of the endometrial carcinoma drug market","url":"https:\/\/www.nature.com\/articles\/d41573-022-00016-2","name":"The endometrial carcinoma drug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAkc-MEB_Zujnlt3eKoAqUvSe0ATZws6z1E,NAME_SEARCH,jZ5W)"}]},{"publishedOn":{"month":3,"day":4,"year":2022},"description":"News and analysis of bispecific antibodies in oncology including a major-market drug forecast","url":"https:\/\/www.nature.com\/articles\/d41573-022-00040-2","name":"Bispecific antibodies in oncology","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAChecSwBN1ThToNT3Jal9nTLcTj0dJmNWLQ,NAME_SEARCH,40W4)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAQvGZsBQsQPqiYByIB78dFsElqpdmksvg8,NAME_SEARCH,rSeg)"}]},{"publishedOn":{"month":4,"day":27,"year":2022},"description":"News and analysis of the malignant melanoma market","url":"https:\/\/www.nature.com\/articles\/d41573-022-00075-5","name":"The malignant melanoma market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcu-aIB1WJlQjXwKN4wa-d24UnScmagTFM,NAME_SEARCH,UC-V)"}]},{"publishedOn":{"month":1,"day":23,"year":2023},"description":"News and analysis of the NSCLC market","url":"https:\/\/www.nature.com\/articles\/d41573-023-00017-9","name":"The non-small-cell lung cancer drug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHq3HYBmo5LNgFVoJBkL8regfojP87-EdE,NAME_SEARCH,dvus)"}]},{"publishedOn":{"month":11,"day":21,"year":2023},"description":"News and analysis of the renal cell carcinoma drug market","url":"https:\/\/www.nature.com\/articles\/d41573-023-00186-7","name":"The renal cell carcinoma rug market","publisher":"Nature Reviews Drug Discovery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHw8i8BmIbZO5FLb8pEGCE1kHPQm59AYU4,NAME_SEARCH,lr8Y)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA2CQ9kBFx-QgwwPYnANaSnxv-r-0gYPs5I,NAME_SEARCH,K760)"}]}],"positions":null,"posts":[{"createdAt":1715170020000,"insightId":"1fcd3037-1a33-4e78-b803-b332a997ca55","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":23},{"type":"EMPATHY","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7193944475851780096","threadUrn":"urn:li:activity:7193944475851780096","reactionsCount":25,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7193944475394600960","message":{"attributes":[],"text":"Come and join our talented team of oncology market assessment experts in producing world-class solutions and insights to our global pharmaceutical customers. Apply now!\u00a0"},"rootActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:job:3916796591"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7193662530299297792","message":{"attributes":[{"start":67,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:32567855"}}},{"start":84,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:32169078"}}}],"text":"Very exciting position in Barcelona for an Oncology expert to join Rachel Webster & Khurram Nawaz team. \n\u00a0\nYou will contribute oncology therapeutic expertise and translate market research data into high-quality syndicated and custom insights to our global pharmaceutical customers. \n\u00a0\nIf you have passion for the dynamic oncology landscape and excited about the opportunity to work in the market assessment field within our vibrant Life Sciences & Healthcare (LS&H) group, we would like to hear from you.\n\u00a0"},"entityUrn":"urn:li:share:7193662530299297792"},"entityUrn":"urn:li:share:7193944475394600960"}}},{"createdAt":1715169780000,"insightId":"6ccc7791-1a8a-4435-a009-23fd1678dc91","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7193572175520366594,7193943667005419520)","threadUrn":"urn:li:activity:7193572175520366594","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Delighted that you back, Alison!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7193572175520366594"}}}]}